Eisai Begins Construction Of Antibody Plant In U.S.
This article was originally published in PharmAsia News
Executive SummaryEisai March 9 announced the start of construction of an antibody drug production site adjacent to its Pennsylvania-based U.S. subsidiary Morphotek
You may also be interested in...
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.